Humans coexist with a vast bacterial, fungal and viral microbiome with which we have coevolved for millions of years. Several long recognized epidemiological associations between particular bacteria and cancer are now understood at the molecular level. At the same time, the arrival of next-generation sequencing technology has permitted a thorough exploration of microbiomes such as that of the human gut, enabling observation of taxonomic and metabolomic relationships between the microbiome and cancer. These studies have revealed causal mechanisms for both microbes within tumours and microbes in other host niches separated from tumours, mediated through direct and immunological mechanisms.
An overview of the human microbiome
Bacteria, fungi and viruses are widely present on epithelia, including general and specialized epidermal surfaces [1] , the nares, the respiratory tree [2, 3] , the ductal system of exocrine organs, including the breast [4] , the vagina [5] , and the gastrointestinal (GI) tract [6] . Bacteria routinely cross the GI mucosa and are further exposed to the enterohepatic circulation [7] ; a small number may circulate in the blood from time to time, and there is evidence that some even concentrate in tumours, owing to the aberrant tumour vasculature permitting residence and extravasation (Table 1 ). An explosion of next-generation sequencing studies has enabled the identification and relative quantification of the species present in each of these microbiota, without the bias introduced by traditional methods of bacterial culture, and thus the metabolic and population responses of microbiota to changes in their microenvironment are becoming increasingly understood. The majority of this review will focus on the relationships between the gut microbiome and cancer, but some attention will also be given to the microbiome of tumours themselves.
The availability of high-depth next-generation sequencing of bacterial 16S ribosomal RNA has enabled the identification and relative quantification of vast numbers of organisms in the gut microbiome. With such data came the recognition that the majority of species were not routinely culturable, which has, over the last decade, led to the exploration of far more culture techniques [8] , with a particular emphasis on the anaerobes that constitute the majority of a typical microbiome, but a minority of routinely cultured organisms. More recently, with the increasing availability of high-throughput sequencing, better sequence assembly techniques, and far more complete databases of sequenced organisms [9, 10] , high-depth metagenomic sequencing has come to the fore [11] , enabling the identification and quantification of organisms from a mixed metagenomic sample, such as stool or a mucosal biopsy, down to the individual bacterial strain, as well as revealing the virome interwoven with the bacterial microbiome [12, 13] . The basic results of these studies are staggering. The typical human gut microbiome includes 10 13 -10 14 organisms, which is similar to the number of human cells [14] , as well as a unique genome of up to 3 × 10 6 genes, in vast excess over the human genome. Most organisms with a gut analysed to date have a microbiome (with a couple of remarkable exceptions [15] ), which has coevolved in symbiosis with the host for millions of years. The bacterial microbiome supplies a diversity of metabolic functions far beyond that available in the host genome. Conversely, the microbiome is fed and shaped by the host diet, while being controlled by the immune system and epithelial interactions, to meet the nutritional needs of the host.
Four phyla of bacteria predominate in the human gut microbiome (Figure 1 ). The Firmicutes and Bac Geller et al (2017) [83] well as streptococci and enterococci. The Bacteroidetes are Gram-negative rods with extensive ability to digest complex carbohydrates, and include the well-known Bacteroides thetaiotamicron and Bacteroides fragilis. The Actinobacteria are high GC content Gram-positive organisms, and include the Bifidobacteria, which are well known as probiotic organisms. The Proteobacteria constitute a diverse group of Gram-negative organisms, and include the Gammaproteobacteria, Escherichia coli, and Klebsiella species. Work in the early 2010s attempted to characterize individuals on the basis of the major constituents of their gut microbiome, resulting in the notion that different humans have different 'enterotypes', influenced by diet and geography [17] , but also in some ways intrinsic to the individual, owing to founder effects of the initial colonizing organisms in infancy and the individual immune system. As more data have accumulated, the picture has simplified, and it appears that most differences between individuals in the microbiome occur along a continuum of the ratio of two genera in the phylum Bacteroidetes, Prevotella and Bacteriodes, with the former being more abundant in humans with a plant-rich diet high in complex polysaccharides [18] . The individual human microbiome appears to be relatively persistent, although Typical major phyla and genera of the human gut microbiome (the genera listed are based on prevalence data from Qin et al [99] ).
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it is occasionally dramatically perturbed by antibiotic treatment [8] ; however, it should be noted that very little study has been made of the effects of deliberate changes in diet. Certainly, much of the microbiome can be repopulated by organisms protected in crypts within the epithelial mucous layer [16] , and interactions between less abundant species may be important for maintenance of the overall structure of the individual microbiome [19] . Studies examining the general association of colon cancer with the microbiome (see below) have yielded varying results, depending on the population examined, but an underpinning theme is that microbiota associated with a plant diet tend to be the ones associated with a lower incidence of colon cancer. A plant-based diet skews microbiota to produce short-chain fatty acids such as acetate, proprionate, and butyrate which have been shown to be anti-inflammatory via induction of T-regulatory cells in colonic tissues [20] .
In parallel with the increased understanding of the constituents of the microbiome, there is an increasing understanding of the immune interactions that occur across epithelial surfaces. Bacteria, bacterial phages and fungi educate both the innate and adaptive immune systems from across the epithelial surface, both by direct interactions with antigen-presenting cells, and by modulation of host signalling with metabolites, in particular short-chain fatty acids such as butyrate [21] . Indeed, some organisms may make products that directly signal through human receptors [22] . Reciprocally, the host preferentially retains or rejects certain organisms by using constraints such as antimicrobial peptides [23] , inactivating IgA [24, 25] , and provision of metabolic substrates such as the proteoglycans of mucins [21, 26] . 
Associative studies of the microbiome and cancer
It is estimated that 20% of tumours worldwide are microbially driven [27] . With modern sequencing approaches, the older epidemiological observations have been supplemented with highly sensitive methods for examining the microbiome more completely in tissues. Several studies using metagenomic techniques identified new pathogens enriched in many different cancer types as compared with either juxtatumoural tissue or the tissues of healthy patients (Table 1) . Tumours arising in sites traditionally assumed to be sterile were also shown to have microbial DNA signatures. Some work has proceeded to define a tumour-specific colonic [28] and laryngeal [29] microbiome. A major question left unanswered from many of these associative studies was whether the organisms had found a tumour niche hospitable as a bystander, or whether the microbes contributed to either the pathogenesis or persistence of the tumour. Some studies of the metagenome and of bacteria associated with tumours are not without controversy, owing to the technological complexity of the studies. These include different representations of the gut microbiome from stool versus biopsy samples, challenges in assigning genes correctly in metagenome studies, and the challenges of interpreting the source of microbial genes in sequencing material from paraffin blocks [30] . Additionally, tumour samples have very low bacterial biomass, meaning that detecting signal over background contamination from DNA extraction kits can be problematic. For example, in one study, the 'kitome' from different lots of DNA extraction kits drove most of the variance in a set of samples observed with metagenomics sequencing [31] . As many laboratories sequence samples using a variety of different techniques for sample extraction, processing, and data analysis, choices regarding these experimental details can change the observed results [32] . Repetition of results across different studies and laboratories is paramount to gain confidence in these results, and work will probably continue to standardize and validate best sequencing practices across the field.
Notwithstanding the immaturity in the field, it seems clear that different organisms can be found in both metastatic and primary cancer sites, possibly as a consequence of haematogenous [33] and local spread from a variety of sources, including the oral plaque microbiome [34] , and these organisms may contribute to tumour inflammation.
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a Cdx2-inducible adenomatous polyposis coli (APC) null mouse model of colon cancer, in which mice develop cancer in the distal colon similarly to the human condition driven by loss of APC, as well as showing an inflammatory interleukin (IL)-23/IL-17 signature, the mouse gut microbiome had a major influence on tumourigenesis via modulation of inflammation [35] . Antibiotic treatment reduced the tumour burden as effectively as knockout of the IL-23 receptor. The mechanism involved innate immune activation via Toll-like receptor (TLR) 2 and myeloid differentiation primary response 88 (MYD88) signalling. Advancing this work in an azoxymethane (AOM)/dextran sulphate sodium (DSS) tumour model, Zackular et al [36] demonstrated that the microbiota of tumour-bearing mice, when transmitted to germ-free recipients, resulted in faster onset and greater severity of colorectal tumours than microbiome transmitted from non-tumour-bearing AOM/DSS mice. This further demonstrated the causative potential for the microbiome to potentiate colorectal tumour growth through inflammation.
Some cancers appear to be critically dependent on their resident microbiome to continue to subsist and evade the immune system, as, when patients are treated with antibiotics, the tumours are effectively treated. The most prominent example is the use of lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg (PREVPAC) for the treatment of Helicobacter pylori-induced gastric mucosa-associated lymphoid tissue (MALT) lymphoma [37] . Another MALT lymphoma, ocular adnexal lymphoma, was shown to driven by Chlamydophila psittaci, as 39 of 44 patients had infection in their tumours [38, 39] . Treatment with doxycycline was effective in inducing complete remission in six patients, and partial remission in 16 patients, in a set of 34 patients treated in total [38] . As expected, levels of chlamydia reduction and removal were consistent with tumour regression. In addition, in a small study of pseudomyxoma peritonei, treatment outcomes were improved with PREVPAC added to the standard regimen of hyperthermic mitomycin C intraperitoneal chemotherapy with tumour debulking [40] .
Mechanistic studies of key carcinogenic organisms
Many constituents of the human virome, such as human papillomavirus and hepatitis B virus, are important carcinogenic pathogens, but they will not be discussed here. The two bacteria most commonly associated with cancer are H. pylori and Fusobacterium nucleatum. Detailed studies of the mechanisms of these organisms, among others, continue to reveal new pathogenetic mechanisms in several of the classes enumerated by Hanahan and Weinberg as drivers of cancer [41] , namely production of genotoxic compounds, protumourigenic inflammation and nuclear factor-κB (NF-κB) activation, downregulation of natural killer (NK) cell-mediated and T-cell-mediated immune surveillance, and increased host cell turnover [42] .
Genotoxic and non-genotoxic bacterial toxins
Specific microbes have been shown to generate genotoxic molecules and other specific toxins that drive cancer. For example, enterotoxic Escherichia coli strains bearing the pks gene cluster produce a polyketide, calobactin, that induces double-strand breaks in mammalian cell DNA [43] . Feeding colorectal cancer (CRC)-prone IL-10 knockout mice with E. coli containing the pks gene leads to increased numbers of tumours. Other inflammatory species of microbes, including Enterococcus faecalis or E. coli lacking pks, resulted in similar inflammation scores but did not exacerbate tumourigenesis [44] ; thus, this model isolated the effects of inflammation from the effects of a specific E. coli-borne genotoxin. The toxigeneic pks gene cluster was found in the metagenome of mucosa-associated colon tissue specimens in 14 of 21 CRC patients and in only five of 24 healthy control humans, further demonstrating a strong association of this microbial gene sequences and CRC [44] .
In contrast, enterotoxin-containing B. fragilis induced tumourigenesis in the APC min/+ model through an inflammation-dependent mechanism [45] . Specifically, activation of Th17 phenotypes through Stat3 activation was required. Thus, bacteria may increase inflammation to increase the overall risk of carcinogenesis, or may additionally provide specific genotoxins to accelerate the process.
Fusobacterium causes inflammation, proliferation, and loss of immune surveillance
Multiple laboratories have observed increases in Fusobacterium species in CRC samples [28, 46, 47] as compared with healthy or precancerous inflamed colon tissues. The multiplicity of geographical locations, age groups, sequencing cores and computational techniques used, all leading to the same observation, lend robustness to the common findings. Most recently, Fusobacterium was also detected in colorectal liver metastases by both culture and metagenomic sequencing, suggesting that colorectal tumour cells provide a specific niche for Fusobacterium [48] . These data were largely associative, and have led to investigation of a causative role for Fusobacterium in CRC.
Isolates of F. nucleatum were able to exacerbate tumourigenesis in the APC min/+ model of CRC when administered orally, but did not did not increase tumourigenesis in inflammation-only models such as IL-10 deletion mice or Tbet/Rag2 deletion mice. This suggests that Fusobacterium served to drive inflammation to accelerate tumourigenesis in a tumour-prone model, but that exacerbation of inflammation was not oncogenic as such in these models [46] .
Increased levels of myeloid-derived suppressor cells (MDSCs) are observed in the microenvironment of Fusobacterium-induced tumours. MDSCs have been shown to exacerbate tumour formation and worsen prognosis in patients [49] , at least in part by interfering with immune surveillance. Fusobacteria appear to thus escape immune attention, and it is conceivable that the reduction in immune surveillance in this milieu also contributes to tumourigenesis. In addition, in vitro mechanistic studies demonstrated the ability of Fusobacterium to bind to TIGIT via its Fap2 adhesin protein [50] . TIGIT is an activating checkpoint protein on NK cells that results in enhanced tumour killing and is a target for pharmaceutical development in immunotherapy [51] . The binding of Fusobacterium to TIGIT resulted in functional blocking of this anti-tumour NK activity, suggesting a plausible mechanism for aiding tumours in avoiding immune destruction [50] .
To further escape immune attention, Fusobacterium has specific functionality making it an invasive pathogen that can live within cells. Specifically, adhesion via the FadA surface protein of Fusobacterium binding to E-cadherin on epithelial cells enables cellular uptake and host cell invasion. Subsequently, this interaction drives production of the inflammatory cytokines IL-6, IL-8 and IL-18 by the epithelial cancer cell line HCT116, as demonstrated in vitro. These inflammatory effects were entirely driven by the invasion of Fusobacterium into host epithelium, as blockade of FadA-mediated uptake of Fusobacterium by clathrin inhibitors prevented cytokine production, and non-invasive Fusobacterium lacking FadA was not inflammatory [52] .
Fusobacterium may also contribute to tumourigenesis independently of the immune system. Fusobacterium binding to E-cadherin induces pro-proliferative β-catenin signalling, which may also contribute to tumourigenesis [52] , in addition to increasing the available intracellular niche for the organism. In a separate study, Fusobacterium culture-positive tumours and quantitative polymerase chain reaction Fusobacterium-negative human tumours (both primary and hepatic metastases) were used to generate patient-derived xenograft models. Interestingly, the authors observed that only Fusobacterium culture-positive tumours were capable of engrafting. Tumours propagated over four generations retained the microbial species as part of the tumours. When these tumours were treated with metronidazole in vivo, the Fusobacterium load dropped significantly, and tumour proliferation rates were decreased. These data point to a role for Fusobacterium supporting tumour growth in an immune-independent manner [48] . Taken together with the observation that Fusobacterium travels with tumour cells to metastatic sites, this suggests a necessary symbiosis between the organism and the Fusobacterium-associated cancer.
Consistent with the findings in mouse models, Fusobacterium is associated with an inflammatory microenvironment in human samples: increased Fusobacterium carriage in tumour tissue is associated with increased levels of NF-κB transcripts [46, 52] and decreased CD3-positive T-cell loads, as well as a worse prognosis, further suggesting that this microbe is associated with tumours that lack antitumour immune cell mechanisms [53, 54] . It should be noted that additional microbial species appear to inhabit similar locations as Fusobacterium, including species of Bacteroides, Selenomonas, and Leptotrichia [48, 55] .
Given the extensive relationship between the gut microbiome and cancer, it is worth noting that Crohn's disease patients with a dysbiosis marked by increased levels of Fusobacterium species, among others, as well as reductions in the Bacteroidetes and Bifidobacteriaceae [56] , have a higher incidence of the majority of common cancers both in the GI tract and outside of the gut [57] .
H. pylori, which is known for its association with both lymphoma and gastric epithelial cancers, appears to use many parallel mechanisms to induce cancer
The most well-studied and famous example of the role of bacteria in driving carcinogenesis is that of Helicobacter leading to gastric MALT lymphoma and gastric adenocarcinoma [58] . H. pylori has been classified as a class 1 carcinogen [27] . Detailed studies of H. pylori have revealed capabilities that allow it to colonize hosts, manipulate the immune system, and drive key hallmarks of cancer, including tumour-promoting inflammation, downregulation of antitumour immune destruction, and increased proliferative signalling.
H. pylori has a host of persistence mechanisms allowing it to induce tumourigenic processes over time. Specifically, H. pylori is able to drive through the thick gastric mucous layer via flagella and adhere to gastric epithelial cells through the presence of multiple adhesins, including SabA and BabA [59, 60] . Once it is intimately associated with epithelium, H. pylori utilizes its type IV secretion system to deposit CagA and other virulence factors on human cells. Once inside the cell, CagA dysregulates SHP2, a host oncoprotein, leading to uncontrolled cell growth and motility [61] . Other virulence factors such as VacA form pores in host membranes, inducing cell death and higher rates of cell turnover [62] .
In addition to directly impacting on the epithelium through toxigenic factors, H. pylori manipulates the inflammatory milieu, producing a cauldron of chronic inflammation with induction of innate inflammatory signals. H. pylori infection induces reactive oxygen species (ROS) production by neutrophils and macrophages, and the production of inflammatory cytokines, including IL-1β, tumour necrosis factor-α, and IL-8, which ultimately drives Th1 immune behaviour in the gut. Additionally, the level of NF-κB is increased in patients with infection, further driving inflammatory mechanisms associated with tumour initiation and progression. Similarly to what is seen for other pathogens, the catalase and superoxide dismutase proteins of H. pylori
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protect it from these ROS, and host tissues are damaged because of bystander effects. Specifically, it was shown in vitro that H. pylori-induced infection resulted in increased DNA damage in host cells [63] . Over time, DNA damage results in increased mutational loads.
In addition to the broad innate immune signalling effects that H. pylori induces, there are several interesting adaptive immune effects, specifically on T cells, that occur as well. The pathogen virulence factor VacA blocks nuclear factor of activated T cells (NFAT) activation in T cells, leading to a deficiency of IL-2-driven T-cell proliferation, which would normally result in clearance of H. pylori [62] . Additionally, γ-glutamyltranspeptidase (GGT) of H. pylori is also able to block T-cell proliferation [64, 65] . This results in skewing away from Th1 and Th17 immune responses against the specific pathogen, and increased skewing towards regulatory T-cell responses. This is important in generating a persistent infection, and probably results in reduced immune surveillance against tumours. Thus, the combination of cellular damage, innate procarcinogenic signals and reduced immune surveillance forms a perfect storm in a small subset of patients, resulting in cancer. Additionally, H. pylori has been shown to induce programmed death-ligand 1 (PD-L1) expression on gastric epithelial cells, which, in turn, regulates T-cell programmed cell death 1 (PD-1), leading to loss of immune surveillance [66] . This is a vital tumour escape mechanism, is associated with checkpoint-mediated tumour progression, and consequently has been an important therapeutic target [67] .
Although the focus of this review is predominantly on the cancer-inducing aspects of H. pylori and other microbes, it is worth noting that the immune-activating mechanisms, which are locally tumourigenic, actually have beneficial effects in the systemic immune system. H. pylori carriage has been shown to be protective against asthma, atopic disease, inflammatory bowel disease, and Barrett's oesophagus, which is a precursor to oesophageal adenocarcinoma [68, 69] . These observations demonstrate the complex interplay between microbiota and immune tone resulting in a vigilant but not overactive immune system.
Propionobacterium and tumourigenesis in the prostate
Bacterial-related tumourigenesis does not appear to be limited to the GI tract. Propionobacterium acnes has been observed as a constituent of prostate cancers by several groups using culture techniques, fluorescence microscopy, and nucleic acid detection [70] [71] [72] . Interestingly, these P. acnes strains had radically different surface properties from those of P. acnes strains associated with skin samples. Furthermore, these tumour-associated bacteria were able to infect and invade host cells and induce cyclooxygenase-2 (COX-2) signalling, serving to enhance cell proliferation in vitro.
In vivo, P. acnes recovered from prostate cancer patients induced increased inflammation and cell proliferation when administered to the prostate of mice [73] .
Distal oncogenic effects of bacteria
The gut microbiota has also been shown to exert effects on tumourigenesis beyond the GI and mucosal membranes. Because of the physiological link between the liver and the gut via the portal circulation, the liver is often impacted by alterations in the GI microbiome.
In an inflammatory and fibrotic model of hepatocellular carcinoma (HCC), in which mice are treated with a single dose of diethylnitrosamine and repeated doses of the hepatotoxin carbon tetrachloride, partial ablation of the gut microbiome with antibiotics was shown to inhibit carcinogenesis. Antibiotic administration was still effective extremely late in the progression of the disease model when fibrosis was already apparent, indicating that the liver fibrosis and inflammation did not by themselves result in HCC. Oncogenesis was shown to be dependent on TLR4 activation in resident liver cells, as complete knockouts of TLR4 in the mouse, or liver-specific knockouts, resulted in reduced tumor numbers and tumor size in the model. It is important to note that the major ligand of TLR4 is bacterially derived lipopolysaccharide (LPS). Bone marrow from TLR4 wild-type animals was not able to restore the oncogenic effect of the microbiota in a TLR4 knockout host, pointing to resident cells in the liver driving the oncogenic effect of the microbiota [74] . Taken together, these findings suggest that microbiota-derived LPS, the major ligand of TLR4 activation, potentiates tumourigenesis.
In another model, an effect of the microbiome on host bile acids was the oncogenic driver [75] . Primary bile acids are produced in the liver and secreted into the small intestine, where they are modified by bacteria to produce deconjugated, secondary and tertiary bile acid moieties, which are reabsorbed by the intestine and reach the liver via the portal circulation. A secondary bile acid derivative, deoxycholic acid (DCA), is particularly carcinogenic and induces DNA damage in hepatocytes [75, 76] . DCA also induces senescence in hepatic stellate cells, which results in an inflammatory liver environment. High-fat diets result in the expansion of the Clostridium XI and XIV clusters, which modify bile to produce increased levels of DCA. Thus, a high-fat diet, combined with a microbiome enriched in bile acid-modifying clostridia, resulted in progression from non-alcoholic steatohepatitis to HCC. Treatment with a cocktail of antibiotics or vancomycin alone, to which clostridia are sensitive, prevented tumourigenesis. Delivering DCA even in the presence of antibiotics restored tumourigenesis, clearly implicating bacterially produced DCA as the carcinogen in the system. In addition, the microbiome induced inflammatory signals, including IL-6 and IL-1β [75] . Although less concretely linked to Clostridium species, it is possible that similar mechanisms drive oesophageal cancer [76] .
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The microbiome and its components as cancer-curing agents So far, we have summarized the roles of specific organisms and microbiota as cancer-causing and cancer-promoting agents. In contrast, many constituents of the microbiome can, in certain circumstances, interact with the immune system to be protective against cancer. Microbial-based immunotherapy started with anecdotal observations of cancer cures after serious infections, followed in the late 19th century by the use of Coley's toxins in sarcomas [77] , and, from the 1970s until the present day, the use of Bacillus Calmette-Guérin (BCG) as a topical intravesical therapy for bladder cancer [78] . The resurgence of immunotherapy in the last decade with the use of checkpoint inhibitors has revealed a very important role for the microbiome in modulating the antitumour immune environment.
Specific bacterial products in cancer therapy
The foundational observations for immunotherapy were made by William Coley, when he first observed a patient with terminal sarcoma who was cured and well, many years after receiving his treatment. Upon inspection of the patient, Coley realized that a bacterial infection had induced an antitumour effect, saving this man's life (retold in [79] ). This inspired Coley's life work, during which he was able to achieve therapeutic benefit by administering combinations of heat-killed Streptococcus pyogenes and Serratia marcescens to treat patients (reviewed in [80] ). Although this combination was effective and possibly curative in a small proportion of patients, it fell out of favour when radiotherapy, with the latter's more consistent results, was adopted in the early 1900s. Since then, there has been an accumulation of accounts of the association of tumour cures or remissions with specific microbial infections. For example, postoperative empyema with lung cancer surgery was observed to be associated with increased overall survival [81] .
Concerted work starting in the 1970s led to the attenuated Mycobacterium bovis strain BCG, which was primarily used as a vaccine against tuberculosis, becoming an accepted therapy for use as an immunostimulator for stage 0-1 non-muscular invasive bladder cancer. When BCG is instilled into the patient's bladder after surgical resection, it induces a potent antitumour immune effect. It seems to use a variety of immune-stimulating mechanisms to induce the antitumour response [78] . In a head-to-head clinical trial, two different BCG strains, Connaught and Tice, showed remarkably different efficacies. Preclinical mouse models showed the Connaught strain to be more inflammatory and induce stronger Th1 immune activity. Although the two strains were genetically very similar overall (and derived from the same isolate in the 1920s), Connaught was found to differ from Tice in the predicted activity of superoxide dismutase, probably resulting in its greater persistence [82] .
More exploration of mechanisms and strain-specific differences linked to clinical efficacy could aid in future therapeutic development.
The microbiome as a modulator of chemotherapy
It was recently shown that pancreatic cancer in humans contains a tumour microbiome enriched in members of the Gammaproteobacteria, including Mycoplasma hyorhinis [83] . When transferred to mice, these microbes in pancreatic tumours induced gemcitabine resistance through the microbial destruction of drug in the tumour microenvironment. When mice harbouring the microbes were treated with the antibiotic ciproflaxin, the antitumour effect of the chemotherapeutic gemcitabine was restored [83] .
Irinotecan metabolism is an example where bacterial β-glucuronidase activity induces more severe side effects, including dose-limiting diarrhea, in some patients by reactivating the drug in the colon [84] . There have been several examples of drug metabolism being modified by the microbiome, and this will probably be a continued area of study [85] .
The efficacy of cyclophosphamide has also been shown to be dependent on the microbiome, in this case working through an immunological mechanism [86] . In this context, cyclophosphamide induces a leaky gut by direct epithelial injury, resulting in increased trafficking of gut microorganisms to the gut-associated lymphoid tissue and activation of antitumour Th17 responses.
Microbial modulation of immunotherapy efficacy
The increasing use of checkpoint inhibitors has led to considerable efforts to identify the cause of non-response. In back-to-back publications in 2015, the laboratories of Zitvogel and Gajewski identified components of the microbiome that dictated the response of murine isograft tumours to cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and PD-L1 inhibition, respectively. The Zitvogel study [87] was motivated by the observation that patients treated with anti-CTLA4 develop antibodies against gut flora. Exploration in several different mouse isograft models revealed that the efficacy of CTLA4 inhibition was largely abrogated by antibiotic treatment, and could be rescued with specific organisms, in particular B. fragilis. The antitumour effect could be achieved with oral treatment with B. fragilis, with immunization with B. fragilis-derived polysaccharides, or even by adoptive transfer of B. fragilis-reactive T cells. Other microbiome changes in mice treated with anti-CTLA4 included an increase in the abundance of Bacteroides thetaiotamicron, whose abundance was noted to be inversely proportional to tumour size.
The Gajewski study [88] focused on the observation that, of two genetically identical populations of C57/Bl6 mice from two different suppliers, only one showed inhibition of B16 melanoma growth when treated with a PD-L1 inhibitor. When mice from the two populations were co-housed, both showed response to PD-L1 674 B Goodman and H Gardner inhibition. One of the active components transferred by co-housing was found to be a strain of Bifidobacterium, which was efficacious when delivered orally, but not effective when previously heat-inactivated. Examination of the antitumour activity in mice so treated revealed intratumoural dendritic cells primed for cross-presentation of antigens, and enhanced infiltration of activated CD8 T cells.
In all of these isogenic tumour models, there was no evidence that the active organism had cross-reactive epitopes with the tumour; instead, dendritic cell activation in the gut, and subsequent non-specific priming of effector T cells, appeared to be the primary mechanism of action.
More recent epidemiological studies of the relationship between anti-PD-1 response and gut flora in humans have led to quite dramatic observations of differences in tumour response in response to checkpoint inhibitors, depending on history of antibiotic use (bad) and the presence of particular microorganisms (good). In one study predominantly performed in France, the presence of the organism Akkermansia mucinophilia was strongly associated with survival after PD-1 blockade in renal, urothelial and lung cancers [89] . The geographical focus of the study may make it challenging to generalize the findings [90] . Two different studies of melanoma performed in the USA [91, 92] revealed a variety of changes in different organisms and genera associated with response and non-response to PD-1 inhibition. One of these showed that Bacteroides thetaiotamicron was associated with non-response, in contrast to the prior observations in mice, where Bacteroides thetaiotamicron appeared to be protective. The other, in addition to confirming a potential role for Bifidobacterium in antitumour response, recapitulated, at a level that did not reach statistical significance, the major finding made in the French study. In an interesting aside, surveying predictors of checkpoint response from the microbial genome and metabolome, Frankel et al observed that one of the stronger associations with response was with the xenobiotic anacardic acid, which is a potential modulator of macrophage antibacterial activity, derived from cashew nuts, and not itself a bacterial product [93] .
The variable and partially overlapping findings from different studies reflect the relatively small datasets and large geographical diversity in the sample sets thus far examined, which will be rapidly refined with the increasing quantity of available data. Overall, it can be said that alterations in immune education mediated by gut flora strongly affect response to checkpoint inhibitors, and manipulation of this process by treatment with particular microbes may be a valid route to optimizing checkpoint inhibitor response.
Conclusion
Interactions between the host microbiome and cancer are myriad. Microbiota act to influence cancer through many routes, be they direct, via metabolites and toxins, or, crucially, through the innate and adaptive immune systems. A handful of oncogenic bacteria and their mechanisms are reasonably well understood. At the same time, a burgeoning understanding of the taxonomic and metabolic distribution of human microbiota has enabled correlations of particular populations, genera and species with cancer incidence and the efficacy of anticancer interventions. These early findings represent the beginnings of a detailed dissection of mechanism, which will undoubtedly lead to the discovery and development of new cancer treatments and diagnostics derived from the microbiome.
